Evidence map›Paper›PMID 42362555›Full record

ArticleNPJ breast cancer2026

Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE.

Tatsunori Shimoi, Nobuhiro Shibata, Masahiro Kitada, Michiko Tsuneizumi, Mitsugu Yamamoto, Yukinori Ozaki, Yumi Fujimoto, Sayuri Akiyoshi, Naoki Hashimoto, Miki Yamaguchi and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tatsunori ShimoiDepartment of Medical Oncology, National Cancer Centre Hospital, Tokyo, Japan. tshimoi@ncc.go.jp.
Nobuhiro ShibataDepartment of Clinical Oncology, Kansai Medical University Hospital, Osaka, Japan.
Masahiro KitadaDepartment of Breast Disease Centre, Asahikawa Medical University Hospital, Hokkaido, Japan.
Michiko TsuneizumiDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Mitsugu YamamotoDepartment of Breast Oncology, National Hospital Organisation Hokkaido Cancer Centre, Hokkaido, Japan.
Yukinori OzakiDepartment of Breast Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
Yumi FujimotoDivision of Breast Oncology, Saitama Cancer Centre, Saitama, Japan.
Sayuri AkiyoshiDepartment of Breast Oncology, National Hospital Organisation Kyushu Cancer Centre, Fukuoka, Japan.
Naoki HashimotoDepartment of Breast Surgery, Aomori Prefectural Central Hospital, Aomori, Japan.
Miki YamaguchiDepartment of Breast Surgery, JCHO Kurume General Hospital, Fukuoka, Japan.
Yutaka YamamotoDepartment of Breast and Endocrine Surgery, Kumamoto University Hospital, Kumamoto, Japan.
Norikazu MasudaDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroshi TadaDepartment of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Hospital, Sendai, Miyagi, Japan.
Takashi YamanakaDepartment of Breast Surgery and Oncology, Kanagawa Cancer Centre, Yokohama, Kanagawa, Japan.
Yuichiro KikawaDepartment of Breast Surgery, Kansai Medical University Hospital, Osaka, Japan.
Tetsuhiko TairaDepartment of Medical Oncology, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan.
Shizuka NakagawaBiometrics Department, Clinical Development Division, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.
Taizo TakahashiOncology Medical Science Department, Medical Affairs Division, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.
Mari S ObaDepartment of Clinical Data Science, Clinical Research & Education Promotion Division, National Center of Neurology and Psychiatry, National Center of Neurology and Psychiatry Hospital, Tokyo, Japan.
Naoki NiikuraDepartment of Breast Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The JBCRG-C08/ATTRIBUTE (UMIN000041747) study assessed atezolizumab plus nab-paclitaxel's safety and effectiveness in a metastatic triple-negative breast cancer population, including IMpassion130-ineligible patients. The primary outcome was incidence of investigator-assessed adverse events (AEs). Safety and full analysis populations included 149 and 148 patients, respectively; 4.0% of the full analysis population had Eastern Cooperative Oncology Group performance status ≥2 and 7.4% had a history/comorbidity of autoimmune disease (AID) at baseline. AEs occurred in 96.6% of the safety analysis population; serious AEs (SAEs), in 16.8%; and immune-related AEs (irAEs), in 30.9%. irAE incidence was 45.5% in patients with a history/comorbidity of AID. Notable SAEs included pneumonitis (3.4%), diarrhoea, pyrexia, adrenal insufficiency and cardiac failure (1.3% each). Two cases of Grade 5 pneumonitis occurred. Regarding effectiveness, median progression-free survival was 5.6 months (95% confidence interval, 4.2-6.7). This first analysis found no new safety concerns with atezolizumab combination therapy, although patients with AID require careful monitoring.

Identifiers

PMID42362555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.